3.8.2023 23:00:34 CEST | Aqua Bio Technology ASA | Major shareholding
notifications
Reference is made to the stock exchange announcements made by Aqua Bio
Technology ASA ("ABT" or the "Company") on 23 July 2023 regarding the Company
entering into an agreement in principle with the shareholders of Skinteam Norge
AS (the "Sellers") ("Skinteam") and the stock exchange announcements on 23 and
24 July 2023 regarding the Private Placement and the contemplated Subsequent
Offering as described therein. Reference is furthermore made to the stock
exchange notice earlier today, 3 August 2023, regarding entry into of a final
agreement for the Company's acquisition of Skinteam, which also included
information on the Company having secured voting undertakings from shareholders
representing more than 2/3 of the shares in the Company to where they have
undertaken to vote in favour of all resolutions necessary to implement the
Private Placement and the contemplated Subsequent Offering in the upcoming
extraordinary general meeting (the "EGM") that will be held on 24 August 2023.
As a consequence of the voting undertakings, the conditions for completion of
the Private Placement will be satisfied and it is therefore considered to
correct to disclose the change in shareholding at this time. The share capital
increase relating to the Private Placement will be approved by an extraordinary
general meeting of the Company, to be held on 24 August 2023. Blixen Invest AS
(controlled by Edvard Cock) has not been allocated any shares in the Private
Placement.
Following issuance of these new shares, and upon registration of the
corresponding share capital increase in the Norwegian Register of Business
Enterprises and subsequent delivery of such shares, Blixen Invest AS will hold a
total of 1,280,793 shares in the Company, representing 2.80 % of the total
number of shares and voting rights.
The disclosure obligation was triggered by Blixen Invest AS crossing below the 5
% threshold of total number of voting rights and shares in the Company due to
dilution following the Private Placement.
This information is subject to the disclosure requirements pursuant to Sections
4-2 and 5-12 of the Norwegian Securities Trading Act.
DISCLOSURE REGULATION
This information is subject of the disclosure requirements pursuant to section
of 5-12 of the Norwegian Securities Trading Act.
CONTACTS
* Håvard Lindstrøm, 004794132288, hl@aquabiotech.no
ABOUT AQUA BIO TECHNOLOGY ASA
Aqua Bio Technology (ABT) is developing and commercializing sustainable
biotechnology for use in skin care products. ABT's cosmetics ingredients are
highly effective and they provide the cosmetics industry with natural
alternatives to traditional ingredients. ABT is also marketing and distributing
natural skin care products developed by partners towards consumers and
professional users. Aqua Bio Technology is listed on Euronext Expand.
ATTACHMENTS
Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17847556/2526/3502/Download%20announcement
%20as%20PDF.pdf
Recent Comments